

# Gabriele S Merki-Feld

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6532444/publications.pdf>

Version: 2024-02-01

36  
papers

781  
citations

516215

16  
h-index

525886

27  
g-index

37  
all docs

37  
docs citations

37  
times ranked

712  
citing authors

#	ARTICLE	IF	CITATIONS
1	Migraine and Happiness.. Women S Health Reports, 2022, 3, 155-161.	0.4	4
2	Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study. Acta Neurologica Belgica, 2021, , 1.	0.5	1
3	Dealing with Headache: Sex Differences in the Burden of Migraine- and Tension-Type Headache. Brain Sciences, 2021, 11, 1323.	1.1	9
4	Migraine start, course and features over the cycle of combined hormonal contraceptive users with menstrual migraine – temporal relation to bleeding and hormone withdrawal: a prospective diary-based study. Journal of Headache and Pain, 2020, 21, 81.	2.5	10
5	Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. Expert Review of Neurotherapeutics, 2020, 20, 313-317.	1.4	25
6	Effect of desogestrel 75 Åg on headache frequency and intensity in women with migraine: a prospective controlled trial. European Journal of Contraception and Reproductive Health Care, 2019, 24, 175-181.	0.6	11
7	Contraceptive drugs mitigate experimental stroke-induced brain injury. Cardiovascular Research, 2019, 115, 637-646.	1.8	15
8	Effectiveness of the progestin-only pill for migraine treatment in women: A systematic review and meta-analysis. Cephalalgia, 2018, 38, 754-764.	1.8	35
9	Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). Journal of Headache and Pain, 2018, 19, 76.	2.5	64
10	Improvement of migraine with change from combined hormonal contraceptives to progestin-only contraception with desogestrel: How strong is the effect of taking women off combined contraceptives?. Journal of Obstetrics and Gynaecology, 2017, 37, 338-341.	0.4	11
11	Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Journal of Headache and Pain, 2017, 18, 108.	2.5	130
12	Temporal relations in hormone-withdrawal migraines and impact on prevention- a diary-based pilot study in combined hormonal contraceptive users. Journal of Headache and Pain, 2017, 18, 91.	2.5	5
13	Proposal to inform European institutions regarding the regulation of conscientious objection to abortion. European Journal of Contraception and Reproductive Health Care, 2016, 21, 198-200.	0.6	10
14	Positive effects of the progestin desogestrel 75 Åg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days. Journal of Headache and Pain, 2015, 16, 522.	2.5	25
15	Randomized comparison of bleeding patterns in women using a combined contraceptive vaginal ring or a low-dose combined oral contraceptive on a menstrually signaled regimen. Contraception, 2015, 91, 121-126.	0.8	12
16	European Society of Contraception Statement on Contraception in Obese Women. European Journal of Contraception and Reproductive Health Care, 2015, 20, 19-28.	0.6	33
17	Broad Counseling for Adolescents About Combined Hormonal Contraceptive Methods: The Choice Study. Journal of Adolescent Health, 2014, 54, 404-409.	1.2	14
18	A survey on Swiss women's preferred menstrual/withdrawal bleeding pattern over different phases of reproductive life and with use of hormonal contraception. European Journal of Contraception and Reproductive Health Care, 2014, 19, 266-275.	0.6	22

#	ARTICLE	IF	CITATIONS
19	Headache frequency and intensity in female migraineurs using desogestrel-only contraception: A retrospective pilot diary study. <i>Cephalgia</i> , 2013, 33, 340-346.	1.8	37
20	Desogestrel-only contraception may reduce headache frequency and improve quality of life in women suffering from migraine. <i>European Journal of Contraception and Reproductive Health Care</i> , 2013, 18, 394-400.	0.6	27
21	Six years after deregulation of emergency contraception in Switzerland: Has free access induced changes in the profile of clients attending an emergency pharmacy in Zürich?. <i>European Journal of Contraception and Reproductive Health Care</i> , 2012, 17, 197-204.	0.6	8
22	Intention to use a combined contraceptive method and decision after counselling in Switzerland – Swiss data from the European CHOICE study. <i>European Journal of Contraception and Reproductive Health Care</i> , 2012, 17, 119-127.	0.6	12
23	No effect of Implanon® on inflammatory cardiovascular parameters. <i>Gynecological Endocrinology</i> , 2011, 27, 951-955.	0.7	8
24	Implanon use lowers plasma concentrations of high-molecular-weight adiponectin. <i>Fertility and Sterility</i> , 2011, 95, 23-27.	0.5	9
25	Serum concentrations of high-molecular weight adiponectin and their association with sex steroids in premenopausal women. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 180-185.	1.5	19
26	Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use. <i>European Journal of Contraception and Reproductive Health Care</i> , 2010, 15, 413-422.	0.6	19
27	Effects of the progestagen-only contraceptive implant Implanon® on cardiovascular risk factors. <i>Clinical Endocrinology</i> , 2008, 68, 355-360.	1.2	35
28	Partial and complete expulsion of the Multiload 375 IUD and the levonorgestrel-releasing IUD after correct insertion. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 137, 92-96.	0.5	35
29	Comparison of two procedures for routine IUD exchange in women with positive Pap smears for actinomyces-like organisms. <i>Contraception</i> , 2008, 77, 177-180.	0.8	5
30	Clinical experience with NuvaRing® in daily practice in Switzerland: Cycle control and acceptability among women of all reproductive ages. <i>European Journal of Contraception and Reproductive Health Care</i> , 2007, 12, 240-247.	0.6	33
31	Tubal Pathology: The Role of Hormonal Contraception, Intrauterine Device Use and Chlamydia trachomatis Infection. <i>Gynecologic and Obstetric Investigation</i> , 2007, 63, 114-120.	0.7	7
32	A 2-year prospective study on the effects of depot medroxyprogesterone acetate on bone mass response to estrogen and calcium therapy in individual users. <i>Contraception</i> , 2003, 67, 79-86.	0.8	23
33	Long-term effects of combined oral contraceptives on markers of endothelial function and lipids in healthy premenopausal women. <i>Contraception</i> , 2002, 65, 231-236.	0.8	12
34	Effects of two oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 1216-1221.	1.5	25
35	A prospective study on the effects of depot medroxyprogesterone acetate on trabecular and cortical bone after attainment of peak bone mass. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 863-869.	1.1	21
36	Decrease in Endothelin-1 Plasma Levels during the Menstrual Cycle and after Ethinylestradiol Treatment. <i>Annals of Internal Medicine</i> , 1999, 131, 394.	2.0	6